Cover Image
市場調查報告書

膿痂疹:開發中產品分析

Impetigo - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 360913
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
膿痂疹:開發中產品分析 Impetigo - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 41 Pages
簡介

膿痂疹是一種高度傳染性皮膚病。是由兩種細菌膿毒鏈球菌和金黃色葡萄球菌引起的。症狀包括充滿液體的水皰,皮疹,皮膚損傷和腫大的淋巴結。危險因素包括皮膚與皮膚的接觸,皮膚受傷,患有糖尿病並免疫系統受損等。治療有使用抗生素。

本報告提供膿痂疹的治療藥開發情形相關調查分析,提供開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

膿痂疹概要

治療藥的開發

  • 開發中產品概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Foamix Pharmaceuticals Ltd.
  • Laboratories Ojer Pharma S.L.
  • Lytix Biopharma AS
  • Toyama Chemical Co., Ltd.

治療藥的評估

  • Destiny Pharma Ltd
  • Foamix Pharmaceuticals Ltd
  • Laboratories Ojer Pharma SL
  • Lytix Biopharma AS
  • 富山化學工業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9339IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Pipeline Review, H1 2017, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.

Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabetes and having a compromised immune system. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Impetigo - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Impetigo (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Impetigo (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Impetigo (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Impetigo (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Impetigo (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Impetigo (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Impetigo (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Impetigo (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Impetigo (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Impetigo (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Impetigo - Overview
    • Impetigo - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Impetigo - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Impetigo - Companies Involved in Therapeutics Development
    • Destiny Pharma Ltd
    • Foamix Pharmaceuticals Ltd
    • Laboratories Ojer Pharma SL
    • Lytix Biopharma AS
    • Toyama Chemical Co Ltd
  • Impetigo - Drug Profiles
    • FMX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LTX-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mupirocin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ozenoxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XF-70 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Impetigo - Dormant Projects
  • Impetigo - Discontinued Products
  • Impetigo - Product Development Milestones
    • Featured News & Press Releases
      • May 08, 2017: Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX (ozenoxacin cream 1%)
      • Jul 12, 2016: Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada
      • Jun 27, 2016: Medimetriks Pharmaceuticals New Drug Application for Ozenoxacin Cream, 1% Accepted for Review by FDA
      • Jun 27, 2016: Medimetriks Pharmaceuticals Submits a New Drug Application to FDA for Ozenoxacin Cream, 1%, a Novel Impetigo Treatment
      • Jun 12, 2014: Medimetriks Pharmaceuticals Announces that the Second Phase III Study for Ozenoxacin has been Initiated by Ferrer
      • Jun 05, 2013: Ferrer Completes Phase III Clinical Trial Of Ozenoxacin In Adult And Pediatric Patients With Impetigo
      • Feb 22, 2013: Lytix Biopharma Enrolls First Patient In LTX-109 Phase II Proof Of Concept Infection Study
      • Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of Age For New Antibacterial Compound Ozenoxacin
      • Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo And Other Infectious Dermatological Conditions
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Impetigo, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Impetigo - Pipeline by Destiny Pharma Ltd, H1 2017
  • Impetigo - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
  • Impetigo - Pipeline by Laboratories Ojer Pharma SL, H1 2017
  • Impetigo - Pipeline by Lytix Biopharma AS, H1 2017
  • Impetigo - Pipeline by Toyama Chemical Co Ltd, H1 2017
  • Impetigo - Dormant Projects, H1 2017
  • Impetigo - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Impetigo, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top